Lexeo Therapeutics (LXEO) Insider Tanguler Buys 35,000 Shares
Two insiders bought shares of Lexeo Therapeutics, signaling confidence as the stock trades near its 52-week low.
Reviewed by automated data checks against the source filing. How we make and check alerts
Tolga Tanguler bought 35,000 shares of Lexeo Therapeutics, Inc. ($LXEO) on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LXEO is down 0.2% after 1 week, down 4.9% after 1 month and down 43.8% to date (from the $4.70 close on Jun 25, 2026).
LXEO
Lexeo Therapeutics, Inc.
Key Points
- Agger Mette Kirstine and Brenda Cooperstone each bought 35,000 shares of Lexeo Therapeutics on June 25, 2026, totaling 70,000 shares.
- Lexeo Therapeutics' stock recently traded at $4.75, just above its 52-week low of $3.99.
- JP Morgan and Leerink Partners maintain positive ratings on Lexeo Therapeutics, with price targets of $9 and $15, respectively.
Get $LXEO trade alerts by text
We text you when insiders, Congress or big funds trade $LXEO. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Lexeo Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Lexeo Therapeutics, Inc.
On June 25, 2026, insiders Agger Mette Kirstine and Brenda Cooperstone each bought 35,000 shares of Lexeo Therapeutics, Inc. (LXEO) on the NasdaqGM. This brings their total purchases to 70,000 shares, reflecting a strong belief in the company's potential. The stock was trading at $4.75 at the time of the purchases.
Recent Insider Activity
Both insiders made their purchases on the same day, June 25, 2026. This coordinated buying could indicate a shared confidence in Lexeo Therapeutics' future prospects, especially as the stock is currently trading near its 52-week low of $3.99. Earlier in the day, JP Morgan maintained its Overweight rating on Lexeo with a target price of $9, while Leerink Partners kept its Outperform rating with a target of $15.
How Lexeo Therapeutics, Inc. Stock Has Traded
Lexeo Therapeutics' shares have seen some volatility, currently priced at $4.75. This price is just above its 52-week low, which suggests that the stock may be at a favorable entry point for investors. The stock has fluctuated between a low of $3.99 and a high of $10.99 over the past year. The company's market cap stands at approximately $334.7 million, reflecting its position in the biotechnology sector focused on genetic medicine.
Analysts Set New Price Targets
On June 25, 2026, JP Morgan reiterated its Overweight rating for Lexeo Therapeutics with a price target of $9, down from a previous target of $12. Meanwhile, Leerink Partners maintained its Outperform rating and target of $15. The consensus among analysts indicates a generally positive outlook, with a mean target price of $20.3 based on ten analyst opinions.
What Lexeo Therapeutics, Inc. Does
Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, specializing in gene therapies for hereditary and acquired diseases. The company is developing several gene therapy candidates aimed at treating conditions like Friedreich ataxia cardiomyopathy and various inherited cardiac disorders. The recent insider purchases come as the company continues its important clinical trials.
What's Ahead for Lexeo Therapeutics, Inc.
Lexeo Therapeutics is set to report its next earnings on November 4, 2026. As the company progresses with its clinical trials, further insider transactions and updates from analysts will be important to monitor. Remember, the recent insider buying reflects past decisions and may not indicate current positions as the stock evolves.
Related Filing Alerts
Source: Tolga Tanguler's Form 4 filing on $LXEO (Jun 25, 2026). Find the original filing: LXEO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts